Martin Samuel Bates has filed 15 insider transactions across 1 company since June 2023.
Most recent transaction: a option exercise of 4817 shares of Celldex Therapeutics, Inc. ($CLDX) on January 02, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2026 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Common Stock | 4817 | $10.38 | 32,942.0000 | 66,422,000 | 17.13% | 0.01% |
| Jan. 2, 2026 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Incentive Stock Option (Right to Buy) | 4817 | $0.00 | 58,815.0000 | 66,422,000 | 7.57% | 0.01% |
| June 5, 2025 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | A | Incentive Stock Option (right to buy) | 81000 | $0.00 | 81,000.0000 | 66,383 | 9999.99% | 100.00% |
| June 14, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | S | Common Stock | 17172 | $35.42 | 28,125.0000 | 58,871 | 37.91% | 29.17% |
| June 14, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Incentive Stock Option (Right to Buy) | 3201 | $0.00 | 0.0000 | 58,871 | 100.00% | 5.44% |
| June 14, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Incentive Stock Option (Right to Buy) | 16968 | $0.00 | 63,632.0000 | 58,871 | 21.05% | 28.82% |
| June 14, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Common Stock | 16968 | $10.38 | 45,297.0000 | 58,871 | 59.90% | 28.82% |
| June 14, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Common Stock | 3201 | $9.02 | 28,329.0000 | 58,871 | 12.74% | 5.44% |
| June 13, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | A | Incentive Stock Option (right to buy) | 81000 | $0.00 | 81,000.0000 | 58,871 | 9999.99% | 100.00% |
| May 30, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Common Stock | 25000 | $10.38 | 60,128.0000 | 58,871 | 71.17% | 42.47% |
| May 30, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Incentive Stock Option (Right to Buy) | 25000 | $0.00 | 80,600.0000 | 58,871 | 23.67% | 42.47% |
| May 30, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | S | Common Stock | 35000 | $34.05 | 25,128.0000 | 58,871 | 58.21% | 59.45% |
| Jan. 2, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Incentive Stock Option (Right to Buy) | 10750 | $0.00 | 0.0000 | 48,449,000 | 100.00% | 0.02% |
| Jan. 2, 2024 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | M | Common Stock | 10750 | $2.78 | 35,128.0000 | 48,449,000 | 44.10% | 0.02% |
| June 15, 2023 | Celldex Therapeutics, Inc. | $CLDX | Martin Samuel Bates | SVP AND CFO | A | Incentive Stock Option (right to buy) | 80000 | $0.00 | 80,000.0000 | 47,214 | 9999.99% | 100.00% |